Refine
Year of publication
- 2016 (33) (remove)
Document Type
- Journal article (23)
- Book chapter (6)
- Conference proceeding (2)
- Book (1)
- Doctoral Thesis (1)
Is part of the Bibliography
- yes (33)
Institute
- Life Sciences (33) (remove)
Publisher
- Wiley (8)
- De Gruyter (4)
- Elsevier (4)
- Springer (2)
- The Royal Society of Chemistry (2)
- BAN (1)
- Beilstein-Institut zur Förderung der Chemischen Wissenschaften (1)
- Druckerei & Verlagshaus Mainz (1)
- Institut für Holztechnologie (1)
- Koordinierungsstelle Forschung und Entwicklung der Fachhochschulen des Landes Baden-Württemberg (1)
Primäres Ziel und Aufgabe dieser Arbeit ist ... die Entwicklung einer neuen Recyclingmethode für PET, die die Nachteile der bisherigen Verwertungsmethoden vermeidet und unter weitgehendem Erhalt der bereits erbrachten Syntheseleistung definierte Oligomere liefert. Aus diesen können in Folge hochwertige Produkte hergestellt werden.
In der vorliegenden Studie werden typische, kommerziell erhältliche und mit unterschiedlichen Lacksystemen beschichtete MDF für den Küchenbereich hinsichtlich ihres Emissionsverhaltens und deren Oberflächeneigenschaften verglichen: wasserlack-, lösungsmittellack- und pulverlackbasierte Oberflächen. Es zeigt sich, dass eine Pulverlackierung insgesamt zu höherwertigen Produkten führt, sowohl in Bezug auf Kratzbeständigkeit, Haftung und Beständigkeit gegen feuchte Hitze als auch insbesondere in Bezug auf VOC-Emissionen. Die Wasserlackoberflächen schnitten hinsichtlich ihres Emissionsverhaltens deutlich besser ab als die lösemittelbasierten Beschichtungssysteme und zeigten in Bezug auf die Oberflächeneigenschaften mit einer Ausnahme vergleichbare Kennwerte.
This practical guide for advanced students and decision-makers in the pharma and biotech industry presents key success factors in R&D along with value creators in pharmaceutical innovation. A team of editors and authors with extensive experience in academia and industry and at some of the most prestigious business schools in Europe discusses in detail the innovation process in pharma as well as common and new research and innovation strategies. In doing so, they cover collaboration and partnerships, open innovation, biopharmaceuticals, translational medicine, good manufacturing practice, regulatory affairs, and portfolio management. Each chapter covers controversial aspects of recent developments in the pharmaceutical industry, with the aim of stimulating productive debates on the most effective and efficient innovation processes. A must-have for young professionals and MBA students preparing to enter R&D in pharma or biotech as well as for students on a combined BA/biomedical and natural sciences program.
Tumorzellen on the move : mikrosystem-basierter Assay zur Untersuchung der Tumorzellen-Migration
(2016)
Die Invasion von Tumorzellen in umliegendes Gewebe und die Bildung von Metastasen transformieren einen lokal wachsenden Tumor in eine systemische und lebensbedrohliche Krankheit mit schlechter Prognose. Dabei spielt die aktive Migration der Tumorzellen eine entscheidende Rolle. Tumorzellen gelangen durch die aktive Zellbewegung in das Lymph- oder Blutsystem und breiten sich im Körper aus. Bei der Invasion in ein neues Organ migrieren die Zellen ebenfalls wieder in komplexer Weise durch das Gewebe und können schließlich dort Metastasen bilden. Auf Grund der enormen medizinischen Relevanz der Tumorzell-Invasion, wird die Bewegung von Tumorzellen seit Jahrzehnten unter Laborbedingungen umfassend untersucht und ist ein wichtiger Marker für die Aggressivität der Tumorzellen. Zur Bewegungsanalyse gibt es mehrere experimentelle und auch kommerziell erhältliche in-vitro Untersuchungsmethoden. Ziel des interdisziplinären Projektes „MigChip“ ist die Entwicklung, Herstellung und experimentelle Validierung eines Mikrofludik-Chips zur verbesserten, detailgenauen in-vitro Untersuchung der Tumorzellen-Migration.
The reduced research and development (R&D) efficiency, strong competition from generics, increased cost pressure from payers, and an increased biological complexity of new target indications have resulted in a rethinking and a change from a traditional and more closed R&D model in the pharmaceutical industry toward the new paradigm of open innovation. In the past years, pharmaceutical companies have broadened their external networks toward research collaborations with academic institutes, technology providers, or codevelopment partners. To fulfill the demand to reduce timelines and costs, research-based pharmaceutical companies started to outsource R&D activities. In addition, internal R&D processes were adjusted to the more open R&D model and new processes such as alliance management were established. The corporate frontier of pharmaceutical companies became permeable and more open. As a result, the focus of pharmaceutical R&D expanded from a purely internal toward a mixed internal and external model. Today, the U.S. pharmaceutical company Eli Lilly may have established the most open model toward external innovation, as it has integrated its innovation processes with its business model. Other companies are following this more open R&D model with newer concepts such as new frontier sciences, drug discovery alliances, private public partnerships, innovation incubators, virtual R&D, crowdsourcing, open source innovation, and innovation camps.
Clinical development is historically the phase in which a potential new medicine is being tested in phase 2 and phase 3 patient trials to demonstrate the new molecules' efficacy and safety to support the regulatory approval of drugs by health authorities. This relatively focused approach has been considerably expanded by a number of forces from within the pharmaceutical industry and equally important by changes in the healthcare systems. The need to identify the optimal patient population, showstoppers leading to discontinuation of clinical programs, the silent but constant removal of surrogate endpoints for registration, and the increased demand for real-life data which are used to demonstrate the patients' benefit and which have an ever-increasing role for pricing and reimbursement negotiations are today an integral part of this phase.
This chapter will review both the nuts and bolts of clinical development but also recent developments in this area which shape the environment and how the different players have reacted and what options might need to be explored in the future.
Using a Fabry-Pérot-microresonator with controllable cavity lengths in the λ/2-regime, we show the controlled modification of the vibronic relaxation dynamics of a fluorescent dye molecule in the spectral and time domain. By altering the photonic mode density around the fluorophores we are able to shape the fluorescence spectrum and enhance specifically the probability of the radiative transitions from the electronic excited state to distinct vibronic excited states of the electronic ground state. Analysis and correlation of the spectral and time resolved measurements by a theoretical model and a global fitting procedure allows us to reveal quantitatively the spectrally distributed radiative and non-radiative relaxation dynamics of the respective dye molecule under ambient conditions at the ensemble level.
Here we report a simple way to enhance the resolution of a confocal scanning microscope under cryogenic conditions. Using a microscope objective (MO) with high numerical aperture (NA = 1:25) and 1-propanol as an immersion fluid with low freezing temperature we were able to reach an imaging resolution at 160 K comparable to ambient conditions. The MO and the sample were both placed inside the inner chamber of the cryostat to reduce distortions induced by temperature gradients. The image quality of our commercially available MO was further enhanced by scanning the sample (sample scanning) in contrast to beam scanning. The ease of the whole procedure marks an essential step towards the development of cryo high-resolution microscopy and correlative light and electron cryo microscopy (cryoCLEM).
Herein the optimization of the physicochemical properties and surface biocompatibility of polyelectrolyte multilayers of the natural, biocompatible and biodegradable, linear polysaccharides hyaluronan and chitosan by Hofmeister anions was systematically investigated. We demonstrated that there is an interconnection between the bulk and surface properties of HA/Chi multilayers both varying in accordance with the arrangement of the anions in the Hofmeister series. Kosmotropic anions increased the hydration, thickness, micro- and macro-roughness, and hydrophilicity and improved the biocompatibility of the films by reduction (2 orders of magnitude) of the films stiffness and complete anti-thrombogenicity.